A Study of CS3005 in Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects with Advanced Solid Tumors

Phase 1

CStone Pharmaceuticals